259 related articles for article (PubMed ID: 37796107)
1. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
[TBL] [Abstract][Full Text] [Related]
3. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
Corella AN; Cabiliza Ordonio MVA; Coleman I; Lucas JM; Kaipainen A; Nguyen HM; Sondheim D; Brown LG; True LD; Lee JK; MacPherson D; Nghiem P; Gulati R; Morrissey C; Corey E; Nelson PS
Clin Cancer Res; 2020 Apr; 26(7):1667-1677. PubMed ID: 31806643
[TBL] [Abstract][Full Text] [Related]
4. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
7. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
9. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
10. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
[TBL] [Abstract][Full Text] [Related]
12. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
13. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
19. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
